<DOC>
	<DOCNO>NCT00645463</DOCNO>
	<brief_summary>A recently complete clinical drug interaction study CP-945,598 ketoconazole , potent CYP3A inhibitor , show coadministration CP-945,598 ketoconazole result approximately 5-fold increase CP-945,598 total exposure ( AUC ) 4-fold increase Cmax . Therefore , sensitivity CP-945,598 pharmacokinetics ( PK ) less potent CYP3A inhibitor need characterized support label registration . Diltiazem known substrate moderate mechanism-based inhibitor CYP3A enzyme system choose moderate CYP3A inhibitor study clinically relevant medication likely prescribe concomitantly CP-945,598 give increase risk hypertension cardiovascular disease obese patient population .</brief_summary>
	<brief_title>Effect Diltiazem Administration CP-945,598 Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Diltiazem</mesh_term>
	<criteria>No clinically relevant abnormality base upon medical history , physical exam , 12lead ECG , clinical lab test Body Mass Index ( BMI ) ~ 2740 kg/m2 , inclusive Personally sign inform consent document Evidence history significant acute chronic disease Pregnant nursing female Screening PR interval &gt; 220 msec Sitting blood pressure &lt; = 90 mmHg systolic &lt; = 60 mmHg diastolic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>